Alemtuzumab in the treatment of multiple sclerosis.

J Inflamm Res · 2014 · PMC3959804 · PMID 24672254

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

For the coprimary endpoint of relapse rates, there was a highly significant treatment effect in favor of alemtuzumab in both studies, with risk reduction of 55% in the CARE-MS-1 study and of 49% in the CARE-MS-2 study.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.